Prevention of Chronic Kidney Disease Progression

The talk will outline the new concept of applying a 4 pillar approach in the treatment of diabetic and non-diabetic patients with kidney disease, which just became available recently. With the publication of the FLOW study on may 24 last month, the 4 foundational therapies available consist of RASi, SGLT2i, nsMRA and GLP1-RA. Despite these overwhelming advances in halting or retarding CKD progression, implementation barriers of these treatments exist. Many patients driving on the path to kidney replacement therapy will not receive these treatments. The barriers will be discussed.

Christoph Wanner is a senior professor of medicine in the Department of Clinical Studies and Epidemiology, University Hospital of Würzburg and a visiting professor of renal medicine at the Nuffield Department of Population Health, Clinical Trial Service Unit, University of Oxford. 

His research is in the field of diabetic kidney disease, lipid disorders, and rare kidney diseases with a future focus on maintenance or restoration of kidney health. He has published more than 950 pubmed referenced scientific papers and articles (Hirsch Index web of science 108, google scholar 143). He has been principal investigator of the 4D study and a steering committee member of the SHARP, the Empagliflozin studies and the FIND CKD study aiming in improving the management of cardiovascular and kidney disease progression and treatment of kidney failure by dialysis.

Wanner's two landmark studies in this field have been published in 2005 (The 4D Study) and in 2015 and 2016 (EMPA-REG Outcome)

In 2016 he received the highest awards from the European Renal Association (ERA) and the German Society of Nephrology.

Dr. Wanner is currently President of the ERA, being in office June 2020-2024.

University members only.